Tìm theo
Tegaserod
Các tên gọi khác (1) :
  • Tegaserod maleate
Thuốc đường tiêu hóa
Thuốc Gốc
Small Molecule
CAS: 189188-57-6
ATC: A06AX06
ĐG : Murfreesboro Pharmaceutical Nursing Supply , http://www.unitdosesupply.com
CTHH: C16H23N5O
PTK: 301.3867
Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [Wikipedia]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C16H23N5O
Phân tử khối
301.3867
Monoisotopic mass
301.190260383
InChI
InChI=1S/C16H23N5O/c1-2-3-4-7-18-16(17)21-20-10-13-9-19-15-6-5-12(11-22)8-14(13)15/h5-6,8-10,20,22H,2-4,7,11H2,1H3,(H3,17,18,21)/b13-10+
InChI Key
InChIKey=URPUECXJHQGUDU-JLHYYAGUSA-N
IUPAC Name
(E)-1-({[(3Z)-5-(hydroxymethyl)-3H-indol-3-ylidene]methyl}amino)-2-pentylguanidine
Traditional IUPAC Name
tegaserod
SMILES
CCCCC\N=C(/N)NN\C=C1/C=NC2=C1C=C(CO)C=C2
Độ tan chảy
155 °C
Độ hòa tan
1.50e-01 g/l
logP
2.6
logS
-3.3
pKa (strongest acidic)
14.91
pKa (Strongest Basic)
9.8
PSA
95.03 Å2
Refractivity
112.16 m3·mol-1
Polarizability
35.41 Å3
Rotatable Bond Count
7
H Bond Acceptor Count
6
H Bond Donor Count
4
Physiological Charge
1
Number of Rings
2
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Tegaserod is indicated for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation. Irritable bowel syndrome with constipation and chronic idiopathic constipation are both lower gastrointestinal dysmotility disorders. Clinical investigations have shown that both motor and sensory functions of the gut appear to be altered in patients suffering from irritable bowel syndrome (IBS), while in patients with chronic idiopathic constipation, reduced intestinal motility is the predominant cause of the condition. Both the enteric nervous system, which acts to integrate and process information in the gut, and 5-hydroxytryptamine (5-HT, serotonin) are thought to represent key elements in the etiology of both IBS and idiopathic constipation. Approximately 95% of serotonin is found throughout the gastrointestinal tract, primarily stored in enterochromaffin cells but also in enteric nerves acting as a neurotransmitter. Serotonin has been shown to be involved in regulating motility, visceral sensitivity and intestinal secretion. Investigations suggest an important role of serotonin Type-4 (5-HT4) receptors in the maintenance of gastrointestinal functions in humans. 5-HT4 receptor mRNA has been found throughout the human gastrointestinal tract.
Cơ Chế Tác Dụng : Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [Wikipedia] Tegaserod is a 5-HT4 receptor partial agonist that binds with high affinity at human 5-HT4 receptors, whereas it has no appreciable affinity for 5-HT3 or dopamine receptors. It has moderate affinity for 5-HT1 receptors. Tegaserod, by acting as an agonist at neuronal 5-HT4 receptors, triggers the release of further neurotransmitters such as calcitonin gene-related peptide from sensory neurons. The activation of 5-HT4 receptors in the gastrointestinal tract stimulates the peristaltic reflex and intestinal secretion, as well as inhibits visceral sensitivity.
Dược Động Học :
▧ Absorption :
Rapidly absorbed after oral administration, with an absolute bioavailability of approximately 10%.
▧ Volume of Distribution :
* 368 ± 223 L
▧ Protein binding :
98%
▧ Metabolism :
Tegaserod is metabolized mainly via two pathways. The first is a presystemic acid catalyzed hydrolysis in the stomach followed by oxidation and conjugation which produces the main metabolite of tegaserod, 5-methoxyindole-3-carboxylic acid glucuronide. The main metabolite has negligible affinity for 5-HT4 receptors in vitro. The second metabolic pathway of tegaserod is direct glucuronidation which leads to generation of three isomeric N-glucuronides.
▧ Route of Elimination :
Approximately two-thirds of the orally administered dose of tegaserod is excreted unchanged in the feces, with the remaining one-third excreted in the urine, primarily as the main metabolite.
▧ Half Life :
11 ± 5 hours
▧ Clearance :
* 77 +/- 15 L/h [IV administration]
Độc Tính : Oral LD50 in rat is 2000 mg/kg.
Chỉ Định : Provides relief from the symptoms of irritable bowel syndrome including chronic idiopathic constipation.
Liều Lượng & Cách Dùng : Tablet - Oral
Dữ Kiện Thương Mại
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Zelmac
  • Công ty :
    Sản phẩm biệt dược : Zelnorm
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB01079
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5487301
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506519
ChemSpider
http://www.chemspider.com/Chemical-Structure.4589305.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0078-0355-80
PharmGKB
http://www.pharmgkb.org/drug/PA130413154
Wikipedia
http://en.wikipedia.org/wiki/Tegaserod
RxList
http://www.rxlist.com/cgi/generic3/zelnorm.htm
Drugs.com
http://www.drugs.com/cdi/tegaserod.html
... loading
... loading